News

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include

Salix has an exclusive license to the patent protecting Osmoprep from CDC III, for commercialization of Osmoprep in the US. The lawsuit is in response to an abbreviated

Dr Arlen will initially focus on the clinical development program for the company’s novel monoclonal antibody, NPC-1C, which is intended for the treatment of pancreatic cancer. In addition,

The series C round was led by new investor Nomura phase4 Ventures. New investor Westfield Capital Management and existing investors, Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners,

The application to the FDA follows the completion of a randomized, parallel-group, open-label, multicenter Phase III clinical trial that evaluated time to progression (TTP) of the disease with

The compounds arise from Asterand’s R99 development program. They are selective, small molecule prostaglandin receptor agonists that have been shown in preclinical studies to be effective in reducing

The purpose of this multi-center, first-time-in-human, Phase I trial is to enroll patients with advanced solid tumors who have failed standard therapy. Patients will receive four weekly doses

The double-blind, placebo-controlled trial included four groups of 10 subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. After a 28-day

Pursuant to the letter of intent (LOI), Mikhail Kantius will join Boveran Diagnostics as the company’s chief pathologist and director of lab operations and business development for pathology